Delcath Systems Introduces Hepzato Kit in the US for Treating Metastatic Uveal Melanoma (mUM)
Shots:
- Delcath Systems has launched Hepzato Kit and reported its first commercial use for treating metastatic uveal melanoma (mUM) in the US
- The company has launched various websites incl. HEPZATO KIT, HEPZATO KIT REMS, and HEPZATO KIT Access to support the device’s commercial launch and is working with other cancer centers for easy patient access
- Hepzato Kit (melphalan for Injection/Hepatic Delivery System) is a combination drug/device product delivering melphalan directly to the liver through the Hepatic Delivery System (HDS) that allows increased drug exposure in target tissues while minimizing systemic toxicity
Ref: Delcath Systems | Image: Delcath Systems
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
